Literature DB >> 35391602

Expanding the spectrum of SOX1-antibodies in neuropathy: the coexistence of anti-SOX1 and Guillain-Barré syndrome-a case report.

S Coniglio1, G Turchi2, G Giovannini1, M Mazzoli1, S Meletti1,2, Anna Elisabetta Vaudano3.   

Abstract

BACKGROUND AND AIMS: Antibodies against SOX1 (or anti-glial nuclear antibody, AGNA) are partially characterized onconeural antibodies, firstly described in association with small cell lung cancer (SCLC). Lambert-Eaton myasthenic syndrome is the most frequent paraneoplastic syndrome (PNS) found in patients with anti-SOX1-antibody positivity. Other associations are chronic axonal polyneuropathy, paraneoplastic limbic encephalitis, and paraneoplastic cerebellar degeneration.
METHODS: We describe a case of Guillain-Barré syndrome (GBS) with classical demyelinating phenotype associated with a positivity for anti-SOX1-antibodies.
RESULTS: A therapy with intravenous immunoglobulin led to progressive clinical improvement. After 12 months, clinical and neurophysiological pictures showed complete recovery. A thorough paraneoplastic screening was negative for underlying tumors.
CONCLUSIONS: This is the first case of GBS associated with anti-SOX1-antibodies described in literature. Although the concept of paraneoplastic GBS is controversial, different cases have been reported and GBS is considered a non-classical paraneoplastic syndrome. Our case expands the anti-SOX1-antibody clinical spectrum with relevant implications for the clinical practice.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Anti-SOX1-antibodies; Case report; Guillain-Barré syndrome; Paraneoplastic syndrome

Mesh:

Substances:

Year:  2022        PMID: 35391602     DOI: 10.1007/s10072-022-06055-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

Review 1.  The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand?

Authors:  Antonino Uncini; Satoshi Kuwabara
Journal:  Clin Neurophysiol       Date:  2018-10-28       Impact factor: 3.708

2.  Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice?

Authors:  Yusuf A Rajabally; Marie-Christine Durand; James Mitchell; David Orlikowski; Guillaume Nicolas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-05-09       Impact factor: 10.154

3.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

4.  Prevalence of anti-SOX1 reactivity in various neurological disorders.

Authors:  Benjamin Berger; Rick Dersch; Elisabeth Ruthardt; Christiane Rasiah; Sebastian Rauer; Oliver Stich
Journal:  J Neurol Sci       Date:  2016-09-04       Impact factor: 3.181

5.  SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.

Authors:  L Sabater; M Titulaer; A Saiz; J Verschuuren; A O Güre; F Graus
Journal:  Neurology       Date:  2007-11-21       Impact factor: 9.910

6.  Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria.

Authors:  Christiaan Fokke; Bianca van den Berg; Judith Drenthen; Christa Walgaard; Pieter Antoon van Doorn; Bart Casper Jacobs
Journal:  Brain       Date:  2013-10-26       Impact factor: 13.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.